title: American Association of Oral and Maxillofacial Surgeons position paper on medication-related osteonecrosis of the jaw--2014 update.
abstract: Strategies for management of patients with, or at risk for, medication-related osteonecrosis of the jaw (MRONJ) were set forth in the American Association of Oral and Maxillofacial Surgeons (AAOMS) position papers in 2007 and 2009. The position papers were developed by a special committee appointed by the board and composed of clinicians with extensive experience in caring for these patients and basic science researchers. The knowledge base and experience in addressing MRONJ has expanded, necessitating modifications and refinements to the previous position paper. This special committee met in September 2013 to appraise the current literature and revise the guidelines as indicated to reflect current knowledge in this field. This update contains revisions to diagnosis, staging, and management strategies and highlights current research status. The AAOMS considers it vitally important that this information be disseminated to other relevant health care professionals and organizations.
authors.affiliation: Clinical Professor, Division of Oral and Maxillofacial Surgery, Stony Brook School of Dental Medicine, Hofstra North Shore-LIJ School of Medicine, New York Center for Orthognathic and Maxillofacial Surgery, Lake Success, NY. Electronic address: sruggie@optonline.net.
authors.forename: Salvatore L
authors.initials: SL
authors.lastname: Ruggiero
authors.affiliation: Professor and Chair, Associate Dean for Hospital Affairs, Department of Oral and Maxillofacial Surgery, University of Washington School of Dentistry, Seattle, WA.
authors.forename: Thomas B
authors.initials: TB
authors.lastname: Dodson
authors.affiliation: Chief, Division of Oral Pathology, Department of Dental Medicine, Hofstra North Shore-LIJ School of Medicine , New Hyde Park, NY.
authors.forename: John
authors.initials: J
authors.lastname: Fantasia
authors.affiliation: Professor, Department of Oral and Maxillofacial Sciences, Dalhousie University, Halifax, NS, Canada.
authors.forename: Reginald
authors.initials: R
authors.lastname: Goodday
authors.affiliation: Associate Professor, Oral and Maxillofacial Surgery, Assistant Dean for Clinical Research, UCLA School of Dentistry, Los Angeles, CA.
authors.forename: Tara
authors.initials: T
authors.lastname: Aghaloo
authors.affiliation: Director, Cancer Institute at St Francis Hospital, Roslyn, NY.
authors.forename: Bhoomi
authors.initials: B
authors.lastname: Mehrotra
authors.affiliation: Director, Division of Maxillofacial Surgery, Kaiser Permanente Oakland Medical Center, Oakland, CA.
authors.forename: Felice
authors.initials: F
authors.lastname: O'Ryan
mesh_terms: D020533:Angiogenesis Inhibitors / Q000009:adverse effects*; D000970:Antineoplastic Agents / Q000009:adverse effects; D059266:Bisphosphonate-Associated Osteonecrosis of the Jaw / Q000175:diagnosis / Q000209:etiology* / Q000628:therapy; D050071:Bone Density Conservation Agents / Q000009:adverse effects*; D016723:Bone Remodeling / Q000187:drug effects; D001862:Bone Resorption / Q000517:prevention & control; D003937:Diagnosis, Differential; D006801:Humans; D007571:Jaw Diseases / Q000139:chemically induced* / Q000175:diagnosis / Q000628:therapy; D009369:Neoplasms / Q000188:drug therapy; D018919:Neovascularization, Physiologic / Q000187:drug effects; D019647:Oral Surgical Procedures / Q000009:adverse effects; D010020:Osteonecrosis / Q000139:chemically induced* / Q000175:diagnosis / Q000628:therapy; D010024:Osteoporosis / Q000188:drug therapy; D010347:Patient Care Planning; D018570:Risk Assessment; D012307:Risk Factors; D009626:Terminology as Topic; D013997:Time Factors
chemical_list: D020533:Angiogenesis Inhibitors; D000970:Antineoplastic Agents; D050071:Bone Density Conservation Agents